BRPI0817396B8 - composição farmacêutica para tratar deficiência de vitamina b¹² - Google Patents
composição farmacêutica para tratar deficiência de vitamina b¹² Download PDFInfo
- Publication number
- BRPI0817396B8 BRPI0817396B8 BRPI0817396A BRPI0817396A BRPI0817396B8 BR PI0817396 B8 BRPI0817396 B8 BR PI0817396B8 BR PI0817396 A BRPI0817396 A BR PI0817396A BR PI0817396 A BRPI0817396 A BR PI0817396A BR PI0817396 B8 BRPI0817396 B8 BR PI0817396B8
- Authority
- BR
- Brazil
- Prior art keywords
- deficiency
- pharmaceutical composition
- vitamin
- treat vitamin
- treating
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 229930003270 Vitamin B Natural products 0.000 title 1
- 230000007812 deficiency Effects 0.000 title 1
- 235000019156 vitamin B Nutrition 0.000 title 1
- 239000011720 vitamin B Substances 0.000 title 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 abstract 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 abstract 2
- RMRCNWBMXRMIRW-WYVZQNDMSA-L vitamin b12 Chemical compound N([C@@H]([C@@]1(C)[C@@](C)(CC(N)=O)[C@H](CCC(N)=O)\C(N1[Co+]C#N)=C(/C)\C1=N\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NCC(C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO RMRCNWBMXRMIRW-WYVZQNDMSA-L 0.000 abstract 2
- 125000003816 2-hydroxybenzoyl group Chemical group OC1=C(C(=O)*)C=CC=C1 0.000 abstract 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960002446 octanoic acid Drugs 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98489807P | 2007-11-02 | 2007-11-02 | |
US60/984,898 | 2007-11-02 | ||
US2010808P | 2008-01-09 | 2008-01-09 | |
US61/020,108 | 2008-01-09 | ||
US8356608P | 2008-07-25 | 2008-07-25 | |
US61/083,566 | 2008-07-25 | ||
PCT/US2008/082064 WO2009059188A1 (en) | 2007-11-02 | 2008-10-31 | Method of treating vitamin b12 deficiency |
Publications (5)
Publication Number | Publication Date |
---|---|
BRPI0817396A2 BRPI0817396A2 (pt) | 2015-04-07 |
BRPI0817396B1 BRPI0817396B1 (pt) | 2019-04-24 |
BRPI0817396B8 true BRPI0817396B8 (pt) | 2020-02-04 |
BRPI0817396C1 BRPI0817396C1 (pt) | 2020-11-17 |
BRPI0817396C8 BRPI0817396C8 (pt) | 2021-05-25 |
Family
ID=40591491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0817396A BRPI0817396C8 (pt) | 2007-11-02 | 2008-10-31 | composição farmacêutica para tratar deficiência de vitamina b¹² |
Country Status (19)
Country | Link |
---|---|
US (3) | US8022048B2 (pt) |
EP (1) | EP2215047B1 (pt) |
JP (1) | JP5555634B2 (pt) |
KR (1) | KR101344369B1 (pt) |
CN (1) | CN101952241B (pt) |
AU (1) | AU2008318423B2 (pt) |
BR (1) | BRPI0817396C8 (pt) |
CA (1) | CA2704780C (pt) |
CL (1) | CL2010000434A1 (pt) |
CO (1) | CO6280475A2 (pt) |
DK (1) | DK2215047T3 (pt) |
ES (1) | ES2443817T3 (pt) |
HK (1) | HK1146480A1 (pt) |
MX (1) | MX2010004716A (pt) |
NZ (1) | NZ585080A (pt) |
PL (1) | PL2215047T3 (pt) |
PT (1) | PT2215047E (pt) |
RU (1) | RU2469728C2 (pt) |
WO (1) | WO2009059188A1 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2461803B1 (en) * | 2009-08-03 | 2018-10-17 | Emisphere Technologies, Inc. | Fast-acting naproxen composition with reduced gastrointestinal effects |
EP3028709B1 (en) * | 2010-02-24 | 2019-08-28 | Emisphere Technologies, Inc | Oral b12 therapy |
DK3326620T3 (da) | 2010-12-16 | 2020-05-25 | Novo Nordisk As | Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre |
MX355361B (es) | 2011-04-12 | 2018-04-17 | Novo Nordisk As | Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados. |
US8805208B2 (en) * | 2012-02-03 | 2014-08-12 | Tyco Electronics Subsea Communications Llc | System and method for polarization de-multiplexing in a coherent optical receiver |
EP4331667A2 (en) | 2012-03-22 | 2024-03-06 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
HUE042757T2 (hu) | 2012-03-22 | 2019-07-29 | Novo Nordisk As | Szállító szert tartalmazó készítmények és elõállításuk |
AU2013234496B2 (en) | 2012-03-22 | 2017-07-27 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
ES2871328T3 (es) | 2012-06-20 | 2021-10-28 | Novo Nordisk As | Formulación de comprimido que comprende un péptido y un agente de suministro |
US20170348417A1 (en) | 2013-04-11 | 2017-12-07 | Richard Louis Price | Treatment of attention deficit disorders and associated symptoms |
US20140309270A1 (en) | 2013-04-11 | 2014-10-16 | Richard Louis Price | Diagnosis and treatment of a form of autistic spectrum disorder |
US9211284B2 (en) | 2013-04-11 | 2015-12-15 | Richard Louis Price | Diagnosis and treatment of P.R.I.C.E. syndrome |
US10098848B2 (en) | 2013-04-11 | 2018-10-16 | Richard Louis Price | Inositol-containing comestible units and methods of treatment using the same |
US9603812B2 (en) | 2013-04-11 | 2017-03-28 | Richard Louis Price | Treatment of autistic spectrum disorder |
KR102393596B1 (ko) | 2016-04-22 | 2022-05-04 | 리셉터 홀딩스, 인크. | 속효성 식물-계 의약 화합물 및 영양 보충제 |
EA201892396A1 (ru) | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
AU2018345812A1 (en) * | 2017-10-05 | 2020-05-14 | Spoke Sciences, Inc. | Herbal compositions with improved bioavailability |
EA202090890A1 (ru) * | 2017-10-05 | 2020-09-03 | Ресептор Холдингз, Инк. | Состав растительного и синтетического каннабиноида быстрого начала действия и пролонгированного действия |
IL275778B2 (en) | 2018-02-02 | 2023-12-01 | Novo Nordisk As | Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665379A (en) * | 1990-09-28 | 1997-09-09 | Pharmacia & Upjohn Aktiebolag | Lipid particle forming matrix, preparation and use thereof |
US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
US5650386A (en) * | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
US6274564B1 (en) * | 1996-09-18 | 2001-08-14 | William J. Sarill | Compositions of cobalamin and related corrinoids, and uses thereof |
US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6255294B1 (en) * | 1998-12-28 | 2001-07-03 | Allergy Limited | Cyanocobalamin (vitamin B12) treatment in allergic disease |
EP1535625B1 (en) | 1999-04-05 | 2014-01-08 | Novartis AG | Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin |
CA2369591C (en) | 1999-04-05 | 2011-06-14 | Emisphere Technologies, Inc. | Disodium salts, monohydrate, and ethanol solvates |
ES2386263T3 (es) * | 2000-03-21 | 2012-08-14 | Emisphere Technologies, Inc. | Método de preparación de salicilamidas alquiladas mediante un producto intermedio de dicarboxilato |
US7049283B2 (en) | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
NZ529439A (en) | 2001-06-01 | 2005-11-25 | Novartis Ag | Method for orally administering parathyroid hormone (PTH) |
PT1420827E (pt) | 2001-08-17 | 2009-12-15 | Novartis Ag | 5-cnac como agente de administração oral de fragmentos da hormona paratiróide |
US20050054557A1 (en) | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
TW200403052A (en) | 2002-07-17 | 2004-03-01 | Novartis Ag | Use of organic compounds |
AR040737A1 (es) | 2002-08-01 | 2005-04-20 | Novartis Ag | Administracion oral de calcitonina |
AU2003275329B2 (en) | 2002-09-13 | 2008-04-03 | Cydex Pharmaceuticals, Inc. | Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin |
CN100579955C (zh) | 2003-04-04 | 2010-01-13 | 帝斯曼知识产权资产管理有限公司 | N-烷氧基草酰丙氨酸酯的制备方法 |
US6938439B2 (en) | 2003-05-22 | 2005-09-06 | Cool Clean Technologies, Inc. | System for use of land fills and recyclable materials |
JP3924616B2 (ja) | 2003-06-30 | 2007-06-06 | 独立行政法人物質・材料研究機構 | 微小サイズの温度感知素子を用いる温度計測方法 |
EP1643978A1 (en) | 2003-07-04 | 2006-04-12 | Nycomed Danmark A/S | Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
MXPA06000446A (es) | 2003-07-11 | 2006-04-07 | Novartis Ag | Composiciones farmaceuticas de dosis oral que comprenden un agente de distribucion en forma micronizada. |
NZ544645A (en) | 2003-07-23 | 2009-04-30 | Novartis Ag | Use of calcitonin in osteoarthritis |
EP1773351B1 (en) * | 2004-05-06 | 2019-04-24 | Emisphere Technologies, Inc. | Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate |
MX2007001348A (es) * | 2004-08-02 | 2008-03-11 | Bebaas Inc | Composiciones de vitamina b12. |
JP2008509933A (ja) * | 2004-08-13 | 2008-04-03 | エミスフェアー・テクノロジーズ・インク | 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤 |
US20060116334A1 (en) * | 2004-12-01 | 2006-06-01 | Curt Hendrix | Folate based composition for treatment of the cardiovascular system |
GB0427600D0 (en) | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
GB0427603D0 (en) | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
AU2006312117A1 (en) * | 2005-11-04 | 2007-05-18 | Genta Incorporated | Pharmaceutical gallium compositions and methods |
-
2008
- 2008-10-31 ES ES08844673.7T patent/ES2443817T3/es active Active
- 2008-10-31 RU RU2010118423/15A patent/RU2469728C2/ru active
- 2008-10-31 DK DK08844673.7T patent/DK2215047T3/da active
- 2008-10-31 BR BRPI0817396A patent/BRPI0817396C8/pt not_active IP Right Cessation
- 2008-10-31 NZ NZ585080A patent/NZ585080A/en not_active IP Right Cessation
- 2008-10-31 JP JP2010532292A patent/JP5555634B2/ja not_active Expired - Fee Related
- 2008-10-31 EP EP08844673.7A patent/EP2215047B1/en active Active
- 2008-10-31 KR KR1020107010771A patent/KR101344369B1/ko active IP Right Grant
- 2008-10-31 MX MX2010004716A patent/MX2010004716A/es active IP Right Grant
- 2008-10-31 CA CA2704780A patent/CA2704780C/en active Active
- 2008-10-31 US US12/262,677 patent/US8022048B2/en not_active Expired - Fee Related
- 2008-10-31 AU AU2008318423A patent/AU2008318423B2/en not_active Ceased
- 2008-10-31 CN CN200880119724.0A patent/CN101952241B/zh not_active Expired - Fee Related
- 2008-10-31 PL PL08844673T patent/PL2215047T3/pl unknown
- 2008-10-31 WO PCT/US2008/082064 patent/WO2009059188A1/en active Application Filing
- 2008-10-31 PT PT88446737T patent/PT2215047E/pt unknown
-
2010
- 2010-04-30 CL CL2010000434A patent/CL2010000434A1/es unknown
- 2010-06-02 CO CO10066425A patent/CO6280475A2/es active IP Right Grant
-
2011
- 2011-01-21 HK HK11100634.9A patent/HK1146480A1/xx not_active IP Right Cessation
- 2011-08-09 US US13/206,090 patent/US8288360B2/en active Active
-
2012
- 2012-09-14 US US13/618,654 patent/US8557792B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0817396B8 (pt) | composição farmacêutica para tratar deficiência de vitamina b¹² | |
BR112018068565A2 (pt) | combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos | |
BR112015001419A2 (pt) | composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios | |
BR112014008036A2 (pt) | tratamento de rinite | |
MX344787B (es) | Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara. | |
BRPI0415953B8 (pt) | formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada | |
BR112015009559A2 (pt) | uso de composto antissenso na preparação de medicamento para tratamento de cãncer, composto antissenso e composição farmacêutica | |
NZ744233A (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
BR112019003136A2 (pt) | forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo | |
MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
MX2013014071A (es) | Combinacion de tratamiento de sinergia para el tratamiento del carcinoma de celula escamosa de cabeza y cuello. | |
CL2021003474A1 (es) | Producto farmacéutico para terapia enzimática para tratamiento de homocistinuria | |
BRPI0517241A (pt) | composição farmacêutica, e, método para preparar a mesma | |
BR112018073556A2 (pt) | medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato . | |
BR112018074434A2 (pt) | composições farmacêuticas compreendendo safinamida | |
BR112015023368A2 (pt) | método de tratamento de deficiência de vitamina b12 | |
BR112020013750A8 (pt) | Dispensação intranasal de olanzapina por dispositivo olfativo de precisão | |
NZ701274A (en) | Oral b12 therapy | |
BR112015012497A2 (pt) | combinações farmacêuticas | |
BR112018068784A2 (pt) | método para o tratamento de leucemia | |
CL2021000882A1 (es) | Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia. | |
BR112022003687A2 (pt) | Método para tratar tinnitus, composição farmacêutica para administração intranasal, e, dose unitária pulverizável de ocitocina | |
EA201592261A1 (ru) | Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2520 DE 25/04/2019 QUANTO AO INVENTOR. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2520 DE 24/04/2019 QUANTO AO PRAZO DE VALIDADE. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 15A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2746 DE 22-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |